Mouse models were orally given IMA at the dose of 50 mg/kg for three weeks and those treated with deionized water of equal volume served as control. To initially assess the potential adverse effects or tumor growth inhibition effect of IMA treatment in the present study, tumor size and body weight of mouse models were monitored every three days during the whole experiment.
Releasing behavior of PTX-loaded nanomedicine
By using PBS (pH=7.4, 0.01 M) with 0.5% Tween-80 as the release medium, the dialysis bags containing 1 mg PTX-loaded nanomedicines in 1 mL of release medium were incubated in 10 mL of the same medium of at 37 °C with shaking at 100 rpm/min. After sampling at predetermined time points, equal volumes of fresh release medium were added. The concentration of PTX was quantitative analyzed by a HPLC method.
In vivo imaging
After two weeks of IMA treatment ended, mice models were i.v. administrated with DiR-labeled NPs (NPs-DiR) or micelles (Micelles-DiR) at the DiR dose of 0.5 mg/kg. 24 h later, mouse models were subjected to in vivo imaging and then sacrificed and perfused with 4% paraformaldehyde. Tumor xenografts were harvested and the semi-quantitative results of fluorescence intensity were acquired ex vivo under the same imaging system.
Characterization of Micelles-PTX
Particle size, PDI and zeta potential of PTXloaded micelles were analyzed using a Malvern Nano ZS (Malvern Instruments, UK) and compared with that of blank micelles.
